The Europe Liver Disease Diagnostics Market is expected to witness market growth of 6.1% CAGR during the forecast period (2020-2026).
Growing incidences of obesity, metabolic syndrome, diabetes, and cardiovascular diseases that contribute to liver disease are another significant factor that fuels the growth of the liver disease treatment market. In addition, an increase in the incidence of liver disease due to the side effects of other medications such as acetaminophen and poor hygienic and sanitation conditions is projected to drive the demand in the coming years.
Liver disease in the United Kingdom has increased dramatically, particularly in people under 65 years of age - a marked contrast to all other major causes of death that have decreased in younger age groups. The epidemic was caused by alcohol, obesity and hepatitis C. LFTs are usually abnormal due to a number of causes, such as drinking too much, fatty liver due to obesity, infections, rare liver diseases, and certain cancers - but they may be a symptom of potentially fatal liver disease.
The liver is the body's factory, producing vital proteins and breaking down or excreting waste products. Liver disease is usually a silent illness in its early stages. Liver function tests (LFTs) are commonly available blood tests associated with liver damage, so early detection of liver diseases is expected to be possible. Millions of these tests are carried out every year in the United Kingdom by doctors and nurses for a variety of symptoms and conditions ranging from tiredness, yellowing of the skin (in white people) to the whiteness of the eyes due to jaundice.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
Scope of the Study
Market Segmentation:
By End User
By Diagnosis Technique
By Country
Companies Profiled
Unique Offerings from the Publisher
Growing incidences of obesity, metabolic syndrome, diabetes, and cardiovascular diseases that contribute to liver disease are another significant factor that fuels the growth of the liver disease treatment market. In addition, an increase in the incidence of liver disease due to the side effects of other medications such as acetaminophen and poor hygienic and sanitation conditions is projected to drive the demand in the coming years.
Liver disease in the United Kingdom has increased dramatically, particularly in people under 65 years of age - a marked contrast to all other major causes of death that have decreased in younger age groups. The epidemic was caused by alcohol, obesity and hepatitis C. LFTs are usually abnormal due to a number of causes, such as drinking too much, fatty liver due to obesity, infections, rare liver diseases, and certain cancers - but they may be a symptom of potentially fatal liver disease.
The liver is the body's factory, producing vital proteins and breaking down or excreting waste products. Liver disease is usually a silent illness in its early stages. Liver function tests (LFTs) are commonly available blood tests associated with liver damage, so early detection of liver diseases is expected to be possible. Millions of these tests are carried out every year in the United Kingdom by doctors and nurses for a variety of symptoms and conditions ranging from tiredness, yellowing of the skin (in white people) to the whiteness of the eyes due to jaundice.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
Scope of the Study
Market Segmentation:
By End User
- Hospitals, Laboratories and Other End Users
By Diagnosis Technique
- Imaging
- Biopsy
- Endoscopy
- Laboratory tests and
- Other Diagnosis Techniques
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Liver Disease Diagnostics Market by End User
Chapter 4. Europe Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 5. Europe Liver Disease Diagnostics Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
Methodology
LOADING...
